<SEC-DOCUMENT>0001470831-25-000187.txt : 20250911
<SEC-HEADER>0001470831-25-000187.hdr.sgml : 20250911
<ACCEPTANCE-DATETIME>20250911174552
ACCESSION NUMBER:		0001470831-25-000187
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250909
FILED AS OF DATE:		20250911
DATE AS OF CHANGE:		20250911

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Accardi Mario Alberto
		CENTRAL INDEX KEY:			0002074392
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40445
		FILM NUMBER:		251309487

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		C/O CENTESSA PHARMACEUTICALS PLC
		STREET 2:		3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM
		CITY:			CHESHIRE
		PROVINCE COUNTRY:   	X0
		ZIP:			WA14 2DT

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Centessa Pharmaceuticals plc
		CENTRAL INDEX KEY:			0001847903
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR
		STREET 2:		1 ASHLEY ROAD
		CITY:			ALTRINCHAM, CHESHIRE
		STATE:			X0
		ZIP:			WA14 2DT
		BUSINESS PHONE:		44 7391 789784

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR
		STREET 2:		1 ASHLEY ROAD
		CITY:			ALTRINCHAM, CHESHIRE
		STATE:			X0
		ZIP:			WA14 2DT

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Centessa Pharmaceuticals Ltd
		DATE OF NAME CHANGE:	20210224
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>wk-form4_1757627149.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-09-09</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001847903</issuerCik>
        <issuerName>Centessa Pharmaceuticals plc</issuerName>
        <issuerTradingSymbol>CNTA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002074392</rptOwnerCik>
            <rptOwnerName>Accardi Mario Alberto</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CENTESSA PHARMACEUTICALS PLC</rptOwnerStreet1>
            <rptOwnerStreet2>3RD FL., 1 ASHLEY RD, ALTRINCHAM</rptOwnerStreet2>
            <rptOwnerCity>CHESHIRE</rptOwnerCity>
            <rptOwnerState>X0</rptOwnerState>
            <rptOwnerZipCode>WA14 2DT</rptOwnerZipCode>
            <rptOwnerStateDescription>UNITED KINGDOM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>President, Orexin Program</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>1</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2025-09-09</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>M</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>5000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>8.01</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>212566</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2025-09-09</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F2"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>7000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>20</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>205566</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Share Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>8.01</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-09-09</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>M</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>5000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2034-02-01</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                    <footnoteId id="F1"/>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>5000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>35000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.</footnote>
        <footnote id="F2">The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 14, 2025.</footnote>
        <footnote id="F3">1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2024.</footnote>
    </footnotes>

    <remarks>Exhibit 24.2 - Substitute Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Raphael Deferiere, attorney-in-fact</signatureName>
        <signatureDate>2025-09-11</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>centessasubstitutepoa.txt
<DESCRIPTION>EX-24.2 SUBSTITUTE POWER OF ATTORNEY
<TEXT>
SUBSTITUTE POWER OF ATTORNEY

Under the terms of powers of attorney (each, a "Power of Attorney") previously
filed with the U.S. Securities and Exchange Commission, the undersigned was
appointed an attorney-in-fact for the below listed individuals to, among other
things, execute for and on behalf of the following individuals any Form 3, Form
4, or Form 5; Schedule 13D or Schedule 13G; or Form 144, or any amendment(s)
thereto, in accordance with Section 13 or Section 16 of the Securities Exchange
Act of 1934 and the rules and regulations promulgated thereunder, or pursuant to
Rule 144 under the Securities Act of 1933 and the rules and regulations
promulgated thereunder:

Saurabh Saha
Iqbal J. Hussain
Tia L. Bush
Karen M. Anderson
John J. Crowley
Stephen Kanes
Raphael Deferiere
Mario Alberto Accardi
Francesco De Rubertis
Arjun Goyal
Brett I.W. Zbar
Mary Lynne Hedley
Samarth Kulkarni
Carol Stuckley
Mathias Hukkelhoven

In accordance with the authority granted under each Power of Attorney, including
the full power of substitution, the undersigned hereby appoints Raphael
Deferiere as substitute attorney-in-fact, on behalf of the individuals listed
above, with the power to exercise and execute all of the powers granted or
conferred in the original Power of Attorney. For the avoidance of doubt, the
foregoing appointment shall not serve as a revocation of the powers granted to
the undersigned himself in each Power of Attorney.

This substitute Power of Attorney shall remain in full force and effect with
respect to each Power of Attorney until such underlying Power of Attorney is
revoked or terminated, unless earlier revoked by the undersigned in a signed
writing.

Date: 08/11/2025

By: /s/ Gregory Weinhoff
Name: Gregory Weinhoff
Title: Attorney-in-Fact
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
